Seoul St. Mary's Hospital

SEOUL, South Korea, Feb. 26, 2024 /PRNewswire/ -- J INTS BIO announced on the 26th of month that the Phase 1/2 clinical study of its Novel Oral 4th Generation EGFR TKI "JIN-A02" for the treatment of NSCLC has been accepted for poster presentation at the upcoming American Association for Cancer Research (AACR) meeting to be held in San Diego USA from 5 to 10 April. Continue Reading J INTS BIO CI The American Association for Cancer Research (AACR) is an authoritative cancer society and is considered one of the world's top three societies in the field of cancer, along with the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO). J INTS BIO will present a poster during the "Phase I Clinical Trials in Progress" session, which will be held on April 8 from 1:30 to 5:00 p.m. The topic of the presentation is "Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI for 3rd generation EGFR-TKI resistant patients in EGFR mutated advanced/metastatic non-small cell lung cancer". 'JIN-A02', a 4th generation EGFR-TKI, selectively binds to C797S, a mutation that leads to resistance to the use of 3rd generation EGFR-TKIs (such as Osimertinib, Lazertinib), in the treatment of EGFR+ NSCLC. 'JIN-A02' is highly selective for and strongly inhibits NSCLC with C797S double or triple mutations and is expected to show efficacy against intracranial tumors due to its high blood-brain barrier permeability. In August last year, J INTS BIO registered the first patient for the global Phase 1/2 clinical trial of 'JIN-A02' at Severance Hospital in Korea. This clinical study is currently recruiting patients with EGFR mutation-positive and advanced NSCLC at in Korea, including Asan Medical Center and the National Cancer Center, and the University of California (U.C. Irvine). The dose escalation part of the study is now at its 4th dose level, and despite the preceding low dose levels, early efficacy responses were observed in targeted lesions, especially in patients with the C797S mutation. J INTS BIO plans to expand the number of clinical trial sites globally and in Korea, this will include Seoul National University Hospital, Samsung Seoul Hospital, and Seoul St. Mary's Hospital. A J INTS BIO official said, "The global clinical trial for 'JIN-A02' is progressing well and is receiving interest in the global market." Details of the AACR presentation will be released on April 8th. SOURCE J INTS BIO

A collaborative research team develops an absorbent multifunctional nanofiber adhesive hemostat based on a protein biomaterial. In recent news, there has been a case where a patient experienced pain due to a surgical procedure involving sutures, resulting in the unintended presence of gauze within the patient's body. Gauze is typically employed to control bleeding during medical interventions, aiding in hemostasis. However, when inadvertently left in the body, it can lead to inflammation and infection. Addressing this issue, recent research has been published by researchers focusing on a hemostatic agent derived from mussels and silkworm cocoons. This hemostatic agent has garnered attention in the academic community due to its efficacy in clotting blood and its safety within the body. A collaborative team, led by Professor Hyung Joon Cha (Department of Chemical Engineering and the School of Convergence Science and Technology) and Dr. Jaeyun Lee (Department of Chemical Engineering) at Pohang University of Science and Technology (POSTECH), Professor Kye Il Joo (Department of Chemical Engineering and Materials Science) at Ewha Womans University, and Dr. Jong Won Rhie (Department of Plastic and Reconstructive Surgery) at Seoul St. Mary's Hospital of the College of Medicine at the Catholic University of Korea, has developed a bilayer nanofiber membrane hemostat using natural proteins derived from mussels and silkworm cocoons. The findings of this research have been recently published online in the latest issue of Small, an international journal specializing in nanoengineering. Conventional hemostatic agents such as gauze or medical bands are limited to application on the surface of the skin. Although there are certain materials that naturally degrade within the body like fibrin glue and collagen sponges, they necessitate proteins sourced from humans or animals, making them considerably expensive. Moreover, existing hemostatic materials lack consistent adherence to bleeding sites and are prone to infection from external contaminants. In response, the researchers developed a bilayer adhesive hemostat utilizing mussel adhesive proteins that exhibit strong tissue adhesion underwater and silk fibroin extracted from silkworm cocoons. In the research, mussel adhesive proteins demonstrated excellent hemostatic effects including platelet activation. The researchers employed methanol vapor to modify the secondary structure of silkworm silk proteins, resulting in a nanofiber membrane with a hydrophobic outer surface. In light of this, the team engineered a hemostatic agent featuring an inner layer with mussel adhesion proteins for wound adhesion and an outer protective layer entirely composed of silkworm silk proteins. Through animal experiments, the hemostatic agent demonstrated rapid acceleration of tissue adhesion and hemostasis in bleeding wounds, effectively preventing the infiltration of water containing infectious agents such as bacteria. Using two proteins that are both highly biocompatible and biodegradable, the researchers have introduced a novel hemostatic agent capable of clotting blood and providing defense against infection. Professor Hyung Joon Cha of the POSTECH who led the study remarked, "We have validated the exceptional hemostatic performance of a multifunctional topical adhesive hemostatic agent that is derived from nature and is based on degradable proteins in the human body." He added, "We will continue further research to assess its applicability in real-world patient care or surgical settings." The research was conducted with support from the Marine BioMaterials Research Center Program of the Ministry of Oceans and Fisheries and the Mid-Career Research Program of the National Research Foundation of Korea.

A government-funded initiative to seamlessly connect hospitals, government, insurers, and medical device manufacturers in the whole care process based on digital therapeutics and big data has commenced at Yonsei University Health System. Yonsei's Severance Hospital recently started prescribing the insomnia DTx Somzz through the integrated platform called Connect-DTx. HOW IT WORKS Connect-DTx can collect health data from the patient user in near real-time once prescribed for DTx. Doctors can use this data to adjust and personalise their patient's treatment. When used by admitted patients, Connect-DTx can link to the hospital EMR to also collect their data. Beyond the care team, the platform also connects with government regulators and insurers. The National Health Insurance Corporation and the Ministry of Food and Drug Safety, for example, can easily inquire into the progress of DTx-based treatments and process insurance claims and reviews through Connect-DTx. Additionally, DTx manufacturers can track which health institutions are using their products without reaching out to them individually to confirm. Seoul St. Mary's Hospital, Boramae Hospital, Wonju Severance Christian Hospital, Korea University Anam Hospital, and Seoul National University Bundang Hospital are all in the process of onboarding and implementing Connect-DTx. More DTx devices for other conditions, such as dementia, Parkinson's disease, and smoking cessation, will be introduced soon. WHY IT MATTERS In 2022, YUHS received 7.8 billion won ($5.8 million) from the South Korean Ministry of Trade, Industry and Energy to develop Connect-DTx. The aim is to provide convenient and safe access to patient health information collected in near real-time from DTx devices and hospital EMRs. This allows doctors to tap into data and be better informed before making personalised treatments for their patients. It also enables the government and insurers to easily review and process insurance claims. THE LARGER TREND Somzz, an insomnia DTx developed by Aimmed, is the first of its kind to be approved in South Korea. It delivers cognitive behavioural therapy (CBT) that is said to help increase sleep in patients. Just four months after Aimmed's clearance in January 2023, Welt received the second approval for its insomnia DTx called WELT-I. These market approvals come as the number of South Koreans dealing with insomnia increased almost twice over the past decade. Today, at least 15% of the population is dealing with chronic insomnia. CBT has become a first-line treatment for this condition, and incorporating it in mobile applications is helping bridge access to this treatment, which is said to be more effective than popping regular sleeping pills. ON THE RECORD "The development of the Connect-DTx platform has made it possible for industry stakeholders such as medical institutions, government ministries and medical device companies to conveniently and safely utilise medical data as well as provide personalised treatment to patients," YUHS Digital Health Department head Joon-Seok Lim said about Connect-DTx. "We expect this to be a catalyst for an era of cutting-edge medical care based on big data that systematically analyses patients’ daily life algorithms and treatment patterns that were once difficult to ascertain," he added.